Nippon Life Global Investors Americas Inc. Buys 3,030 Shares of AbbVie Inc. $ABBV

Nippon Life Global Investors Americas Inc. raised its stake in AbbVie Inc. (NYSE:ABBV) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,970 shares of the company’s stock after acquiring an additional 3,030 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in AbbVie were worth $11,107,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie during the 2nd quarter valued at about $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie in the 2nd quarter valued at $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie during the second quarter worth $36,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at $39,000. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.84.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Price Performance

Shares of ABBV opened at $214.38 on Friday. The company has a market cap of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. The firm has a 50-day moving average of $226.80 and a 200-day moving average of $216.47. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the business posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.